HIF1A and neoplasm: Also in this issue of the JCI, Bailey, Liu, et al. demonstrate that pharmaceutical or genetic targeting of HIF-1α abrogated PD-L1–mediated immune evasion by suppressing PD-L1 expression on malignant cells and myeloid regulatory cells (MDSCs and TAMs), causing reactivation of TILs and tumor rejection (24).